BDB018 + pembrolizumab

**BDB018 + pembrolizumab** is a combination therapy under investigation for advanced solid tumors that are unresectable, metastatic, relapsed or refractory to standard treatments. BDB018 is a next-generation **Toll-like receptor 7/8 agonist** designed to activate the innate immune system, promoting a local and systemic anti-tumor immune response[1][2]. **Pembrolizumab** is a well-established **humanized monoclonal antibody** targeting the **programmed cell death protein 1 (PD-1)** receptor, thereby enhancing T-cell mediated immune responses against cancers[2]. This combination aims to synergistically boost both innate and adaptive immunity, potentially improving outcomes for patients resistant to existing therapies.

Brand names

Keytruda (for pembrolizumab)

Other names

BDB018 + Keytruda